|
|
|
|
| LEADER |
01879nmm a2200445 u 4500 |
| 001 |
EB001957553 |
| 003 |
EBX01000000000000001120455 |
| 005 |
00000000000000.0 |
| 007 |
cr||||||||||||||||||||| |
| 008 |
210211 ||| eng |
| 100 |
1 |
|
|a Seon, Ben
|
| 245 |
0 |
0 |
|a The development of therapeutic antibodies against oncogenic antigens
|h Elektronische Ressource
|c an interview with Ben Seon
|
| 260 |
|
|
|a London
|b Henry Stewart Talks
|c 2020, 2020
|
| 300 |
|
|
|a 1 streaming audio file (15 min.))
|
| 505 |
0 |
|
|a The development of naked and drug-conjugated antibodies against endoglin and CD75b -- The results of recent clinical trials with both therapeutic antibodies -- Advantages and challenges in the development of naked and drug-conjugated antibodies
|
| 653 |
|
|
|a Immunoconjugates / pharmacology
|
| 653 |
|
|
|a Endoglin
|
| 653 |
|
|
|a Clinical trials
|
| 653 |
|
|
|a Immunoconjugates / immunology
|
| 653 |
|
|
|a Antibodies, Monoclonal / pharmacology
|
| 653 |
|
|
|a Clinical Trials as Topic
|
| 653 |
|
|
|a Antineoplastic Agents / immunology
|
| 653 |
|
|
|a Antineoplastic Agents / pharmacology
|
| 653 |
|
|
|a Cancer / Immunotherapy
|
| 653 |
|
|
|a Antibody-drug conjugates
|
| 653 |
|
|
|a Tumor antigens
|
| 653 |
|
|
|a Receptors, Cell Surface / metabolism
|
| 653 |
|
|
|a Monoclonal antibodies / Therapeutic use
|
| 653 |
|
|
|a Antineoplastic agents
|
| 653 |
|
|
|a Neoplasms / drug therapy
|
| 653 |
|
|
|a Antigens, CD.
|
| 653 |
|
|
|a Antibodies, Monoclonal / immunology
|
| 653 |
|
|
|a Antigens, Neoplasm / immunology
|
| 041 |
0 |
7 |
|a eng
|2 ISO 639-2
|
| 989 |
|
|
|b HST
|a Henry Stewart Talks
|
| 490 |
0 |
|
|a Research and clinical interviews
|
| 500 |
|
|
|a Audio interview. - Title from title frames. - Mode of access: World Wide Web
|
| 856 |
4 |
2 |
|u https://hstalks.com/bs/p/1060
|3 Series
|
| 856 |
4 |
0 |
|u https://hstalks.com/bs/3776
|x Verlag
|z Streaming video file
|
| 082 |
0 |
|
|a 570
|